Syndeio Biosciences, Inc
9
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
11.1%
1 terminated/withdrawn out of 9 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
50%
2 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Role: lead
Zelquistinel in the Treatment of Major Depressive Disorder
Role: lead
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Role: lead
Pharmacokinetics of Zelquistinel in Fasted or Fed State
Role: lead
Safety and Tolerability of Zelquistinel in Normal Human Volunteers
Role: lead
Apimostinel + Automated Neurocognitive Training for Depression
Role: collaborator
AGN-241751 in the Treatment of Major Depressive Disorder
Role: lead
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
Role: lead
Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
Role: lead
All 9 trials loaded